JAZZ News and Press, Jazz Pharmaceuticals plc From 06/28/22

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced top-line results from the Phase 3 RELEASE MSS1 trial ( NCT04657666 ) evaluating nabiximols oromucosal spray (JZP378, or Sativex , ex-U.S.) on clinical measures of spasticity in individuals with multiple sclerosis (MS). ...

Jazz Pharmaceuticals (NASDAQ:JAZZ) said its cannabis-based nabiximols oromucosal spray (JZP378) failed to meet the main goal of a late-stage study in patients with multiple sclerosis (MS) spasticity. MS is a potentially disabling disease affecting the central nervous syste...

Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity PR Newswire Nabiximols oromucosal spray continues to be evaluated in ongoing clinical trials in multiple s...

Bear markets don't last forever. They also give forward-thinking investors plenty of opportunities to buy great stocks at a discount. We asked three Motley Fool contributors to identify stocks they think could double by 2025. Here's why they chose Axsome Therapeutics (NASDAQ: AXSM...

AVDL's FT218 is going to get delayed further over a patent issue. However, there's a goalpost in sight now, and the date is June 2023. The company is cash-strapped. For further details see: Avadel: Further Delay, But Some Light At The End Of The Tunnel

The stock market still faces various geopolitical and economic issues, including supply chain problems and interest rate hikes in the U.S. and elsewhere that may impact corporations' bottom lines. In this climate, stocks that look overvalued are more likely to suffer since investors tend to...

Jazz Pharmaceuticals (NASDAQ:JAZZ) is set to initiate a clinical trial for pan-RAF inhibitor JZP815 developed by its partner Redx after the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application, the companies announced on Wednesday. The agency has gree...

UBS has launched its coverage on Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy rating and a $194 per share target, arguing that investors have underestimated the growth prospects of Ireland-based pharma’s cannabidiol drug, Epidiolex. Jazz (JAZZ) recorded ~6% growth of Epidiolex net pro...

Will These 3 Marijuana Stocks See A Recovery Mid-June? Will marijuana stocks start to see better momentum from the success of the cannabis industry? Many publicly traded cannabis companies are making more headway outside of the market than in it. For example companies like Trulieve ...

Top Ancillary Cannabis Stocks For June 2022 Are you looking for the best marijuana stocks to invest in for the long term? The best cannabis stocks to watch right now are recognized for having high market volatility, making it difficult for long-term investors to find stability. Long...